– Seamless, end-to-end, feature-rich membership management system packs a powerful punch – Built by the gym industry for the gym…
Browsing: HealthCare
Cariflex Board of Directors approved the approximate $50 million capital project in April 2020 The new plant is expected to…
Empowers its European Staff to Capture Advanced Medical Knowledge, Promotes Innovation in Technology, and Enhances the Quality and Service Standard…
The leading Asia-Pacific biotech specialist CRO Novotech is again collaborating with the prestigious biotech and pharma news platform Endpoints News.…
With the successive introduction of the “Opinions on Facilitating the Inheritance, Innovation and Development of Traditional Chinese Medicine (TCM)” in…
澳大利亞阿德萊德, 2020年7月9日 – (亞太商訊) – Avance Clinical在全球遠程線上獎頒獎典禮上榮獲由Frost & Sullivan 頒發的久負盛名的“2020亞太CRO市場領導力獎”，其是澳大利亞在CRO 生物技術方面領先的公司。 關於 Frost & Sullivan： “’Frost & Sullivan最佳實踐獎’是對在各自行業中表現出色的頂尖公司的肯定與表彰。獲獎者都是Frost & Sullivan公司分析師進行深入訪談、分析和全方位的二次調研後確定的。通常Frost & Sullivan公司分析師會對候選公司的收入、市場份額、產能和對行業的總體貢獻進行調研，以確定是否符合最佳實踐獎獲得者的要求。” 這是該公司獲得的首個Frost…
The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award…
On February 9, Chinese academician Zhong Nanshan published a retrospective study on novel coronavirus cases in medRxiv, a medical preprint…
Thanks to capital market’s growing expectation for the aging population and accelerated substitution of imported medical devices, China’s medical devices…
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its…
Captiva Verde Land Corp. (CSE: PWR) (the “Company”) is extremely pleased to announce that Solargram Farms Corporation (“Solargram”), a Canadian…
Delivers Solid Performance Amidst Market Challenges; Revenue Increases +6.3%; Maintains Full-Year Dividend Per Share of HK4.5 Cents Jacobson Pharma Corporation…
The largest oncology healthcare group in China, Hygeia Healthcare Holdings Co., Limited (“Hygeia Healthcare” or the “Company”, together with its…
Rehabilitation services designed to keep patients well and prevent their hospital readmission is key to reducing the incidence and cost…
The leading Asia-Pacific biotech specialist CRO Novotech has partnered with South Korea’s world-class Pusan National University Hospital (PNUH) based in…
Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing…
VerifyMe, Inc. (OTCQB:VRME), a digital technology solutions provider specializing in counterfeit prevention, authentication, serialization, data mining, track and trace, features…
Adelaide, AUS, June 11, 2020 – (ACN Newswire) – Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for clinical trials, encouraged biotechs to consider Australia…
澳大利亚领先的生物科技合同研究组织Avance Clinical在今天的生物科技创新组织数字会议上宣布，目前，澳大利亚共有2413个计划或在行测试项目。在澳大利亚，虽然新冠疫情肆虐，健康志愿研究并未中止，只有27个一期或二期研究项目因各种原因暂停（TrialTrove，2020年6月9日）。 Avance Clinical高度赞扬澳大利亚工业界出色的新冠疫情管理能力，这就意味着，澳大利亚在维持临床测试业务方面引领全球。 Avance Clinical首席战略官Ben Edwards在2020年生物科技创新组织数字会议上介绍了澳大利亚临床测试工作的诸多好处。 点击下方链接，查看Avance Clinical生物科技创新组织数字会议演讲稿。 https://www.bio.org/events/bio-digital/sessions/search?name=Avance%20Clinical Edwards先生讲：“大约96%的工作支持中小型生物科技公司，执行一期和二期测试项目。我们的客户遍及北美洲、加拿大、新西兰、欧洲和亚洲。 澳大利亚在国际临床测试方面具有无以伦比的优势。我们对新冠疫情的管理是澳大利亚成为了临床测试最佳目的地。” Avance Clinical是一家以灵活协作的方法闻名的中型全方位服务CRO，在管理早期试验方面拥有20多年的经验。 除了出色的新冠疫情管理能力，另一个重要因素就是速度、高质量场地和运营测试项目成本诱人。 – 澳大利亚政府对临床试验支出提供的43.5%以上的财政退款 – 临床试验无需IND，简化监管流程 -…
Blockchain Holdings Ltd. (Canadian Securities Exchange: BCX) (“BCX” or the “Company”) is pleased to announce that its wholly-owned subsidiary, TraceSafe…